CTRI/2022/05/042392Other1 期
A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone receptor positive, HER-2 negative Advanced Breast Cancer Patients
试验速览
- 阶段
- 1 期
- 状态
- Other
- 入组人数
- 9
- 试验地点
- 7
- 主要终点
- Incidence of dose limiting toxicities at each dose levels (Part 1 only)
研究概览
简要总结
A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and PK and PD characterisation. RP2D will be further evalauted for prelimnary efficacy in MBC patients with tretament failure on Aromatase Inhibitor/Fulvestrant/CDK4-6 inhibitors with or with out ESR1 mutation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •All 3 parts of Study: • Male or females, Age 18 years or older • Histologically or cytologically diagnosed with ER+/HER2- adenocarcinoma of the breast cancer with an evidence of metastatic/loco-regionally recurrent disease/unresectable advanced disease not amenable to treatment with curative intent • Documentation of ER-positive, HER2-negative status determined based on a biopsy performed at or after diagnosis of local or metastatic recurrence, utilizing an assay consistent with local standards • Not more than 3 prior chemotherapeutic regimens • ECOG performance status 0-
- •â€¢ Resolution of all adverse events of prior therapy or surgical procedures to National Cancer Institute (NCI) CTCAE v 5.0 Grade ≤1 (except alopecia) • Adequate organ and immune system function as indicated by laboratory values • Patients of childbearing potential must practice an acceptable method of birth control as judged by the Investigator • Female subjects must be non-lactating and non-breast feeding • Male subjects should not father a child and must practice an acceptable method of birth control measures Willing and available to participate for the entire study • Willing and able to comply with protocol requirements
- •For Part 1& 2: • Patient must have evaluable disease (according to RECIST 1.1).
- •â€¢ Documented disease progression or resistance to at least 1 prior endocrine therapy (with or without CDK 4/6 therapy).
- •For Part 3 • Patient must have measurable lesions (according to RECIST 1.1) • Part 3a: HR+ve, HER2- MBC patients with ESR1 mutations, resistance to atleast one priro endocrine therapy • Part 3b: HR+ve HER2- MBC patients resistant to atleast one priro endocrine therapy • Part 3c: HR+ve HER2- MBC patients resistant to atleast one priro endocrine therapy, disease progression on Fulvestrant and CDK4/6i • Part 3d: Brain metastases secondary to ER+ve HER–ve Breast Cancer: Measurable brain lesion (≥ 1) as per RANO-BM Criteria, Tretament naive/ Treated- Stable/ Not requiring immediate local therapy known/ Suspected leptomeningeal disease on Stable corticosteriod dose for 7 days prior screeing.
排除标准
- •All 3 parts of Study • Major surgery <4 weeks of C1D1 • Evidence of organ dysfunction or inadequate bone marrow reserve or any clinically significant finidngs • Patients with visceral crisis or impending visceral crisis and rapidly progressing disease • Serology tests +ve for HIV, HCV, HBsAg • Inability to swallow oral medication • H/o any relevant allergy/hypersensitivity/idiosyncrasy to drugs/ chemically related to Study drug or its excipients • Received an IMP within 30 days/5 half life to C1D1 • Prior treatment with other oral SERDs • Use of concomitant medication that might reasonably influence the results or interpretation of the study • Requires concurrent systemic anticancer treatment at any time during the study treatment period • Known or suspected history of significant drug abuse/Alcohol as judged by the Investigator • Known or suspected history of excessive intake of alcohol in the 12 months prior to study entry • Malabsorption syndrome/IBD/other illness that would affect oral absorption of Study drug • Uncontrolled intercurrent illness that would limit compliance with study requirements / have impact on endpoints / safety • ≤6 months H/o MI/unstable angina, ongoing > G2 cardiac dysrhythmia, prolonged QTcF/ uncontrolled AF, coronary/peripheral artery bypass graft, HF of NYHA_Class II or greater and CVA (+TIA) • H/o Endometrial intraepithelial neoplasia, other malignancy < 5 yrs prior to enrollment • Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, or leptomeningeal disease as indicated by clinical symptoms (not applicable to Part 3d), carcinomatous meningitis, cerebral edema, and/or progressive growth or pulmonary lymphangitic metastases.
- •â€¢ Current abnormal vaginal bleeding or symptomatic endometrial disorders.
- •For Part 2: Use of other ET that block the estrogen receptor: atleast 8 weeks before enrollment (28 weeks for fulvestrant) For Part 2: Liver-only metastases (are not evaluable by FES-PET/CT imaging)
- •For Part 3: Any brain lesion requiring immediate local therapy (which includes but is not limited to WBRT, SRS, or surgical resection, for treatment of brain metastases) Requires increase in the dose of corticosteroids for control of CNS symptoms due to brain metastases Poorly controlled (> 2 per month ) generalized or complex partial seizures Who are taking concurrent enzyme-inducing antiepileptic drugs (EIAED) Who has evidence of significant (ie, symptomatic) intracranial haemorrhage Contra indications for repeated MRI assessments.
结局指标
主要结局
Incidence of dose limiting toxicities at each dose levels (Part 1 only)
时间窗: 28 Days/End of Cycle 1
次要结局
- Incidence and severity of adverse events with each dose level(The intensity of adverse events will be graded as per CTCAE, Version 5.0 and categorized as serious adverse events or non-serious adverse events.)
- evaluation of Cmax (Part 1 and Part 2)(Pharmacokinetic analysis will be performed using non-compartmental analysis. The actual elapsed time from dose will)
- evaluation of tmax (Part 1 and Part 2)(Pharmacokinetic analysis will be performed using non-compartmental analysis. The actual elapsed time from dose will)
- evaluation of AUC (Part 1 and Part 2)(Pharmacokinetic analysis will be performed using non-compartmental analysis. The actual elapsed time from dose will)
- tumour response(Every 8 weeks, for Time point Response (Partial Response[PR], Stable Disease[SD], Disease)
- pharmacodynamic biomarker(At Screening and End of Cycle 1 (Each Cycle of 28 days))
研究者
研究点 (7)
Loading locations...
相似试验
终止
1 期
A Study in Patients With Advanced Breast CancerHER2-negative Breast CancerHormone Receptor-positive Breast CancerAdvanced Breast CancerNCT04942054Sun Pharma Advanced Research Company Limited9
招募中
早期 1 期
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid TumorsHER2-positive Advanced Solid TumorsNCT05245058Shanghai Pharmaceuticals Holding Co., Ltd150
招募中
1 期
A Study of HS-20122 in Patients With Advanced Solid TumorsNCT06927570Hansoh BioMedical R&D Company1,050
已完成
1 期
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic CancerPancreatic Cancer MetastaticPancreatic Cancer Stage IVStage IV Pancreatic CancerNCT03412799Panbela Therapeutics, Inc.50
撤回
1 期
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid TumorsHER2-expressing or HER2-mutated Locally or Metastatic Solid TumorsNCT06560138Atridia Pty Ltd.20